In clinical practice, serum alpha-fetoprotein (AFP) is usually used as a predictive biomarker for monitoring the prognosis of patients with liver failure because it reflects the regeneration of hepatocytes in response to liver injury (16-18). This evidence concerns the gene AFP and liver failure.